Bayer
Bayer Announces 150 Job Cuts in Basel, Switzerland, Amid Global Restructuring
Bayer layoffs, Basel, Switzerland, consumer health hub, job cuts, restructuring
Bayer Pharma’s Overhaul Not Slowing Down Deal Making, Says BD Chief
Bayer Pharma, deal making, group overhaul, biotech, pharmaceutical industry
Bayer Accelerates Managerial Job Cuts in Ongoing Transformation Efforts
Bayer, managerial job cuts, CEO Bill Anderson, Dynamic Shared Ownership, restructuring, cost savings, pharmaceutical industry
Bayer’s Transformation Accelerates with 3,200 Job Cuts in 2024
Bayer, transformation, job cuts, 2024, Bill Anderson, pharmaceutical industry
Bayer Announces 3,200 Job Cuts, Highlights Progress in Pharmaceutical Pipeline
Bayer, job cuts, pharmaceutical pipeline, cost savings, organizational restructuring
Bayer’s Kerendia Achieves Primary Endpoint in Phase III Heart Failure Study
Bayer, Kerendia, finerenone, heart failure, cardiovascular outcomes, Phase III study, FINEARTS-HF
Bayer’s NUBEQA Shows Promise in Prostate Cancer Treatment, Expanding Indications
NUBEQA, darolutamide, prostate cancer, metastatic hormone-sensitive prostate cancer, non-metastatic castration-resistant prostate cancer, ARASENS trial, ARAMIS trial, Bayer, Orion Corporation
Bayer’s New Drug Shows Promising Phase III Results for Menopause Symptom Relief
Bayer, Phase III results, menopause symptoms, drug, clinical trial, hot flashes, night sweats, hormone therapy
Bayer Initiates Global Workforce Reduction to Streamline Operations
Bayer, workforce reduction, staff cuts, bureaucracy reduction, streamlining operations, global campaign.
Bayer Prepares Menopause Drug Rival to Astellas’ Veozah for Regulatory Filings Following Successful Phase 3 Trials
Bayer, Menopause Drug, Elinzanetant, Phase 3 Hat Trick, Regulatory Approval, Competition with Astellas’ Veozah